Revenue

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our unaudited condensed consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):



	Three Months Ended September 30,				Nine Months Ended September 30,
Businesses	2019		2018		2019		2018
Endoscopy
U.S.	$	277	$	247	$	800	$	724
International	209		196		596		580
Worldwide	486		443		1,396		1,304

Urology and Pelvic Health
U.S.	257		214		737		623
International	102		89		297		280
Worldwide	359		303		1,033		904

Cardiac Rhythm Management
U.S.	284		289		860		869
International	194		186		607		594
Worldwide	478		475		1,467		1,462

Electrophysiology
U.S.	38		37		113		111
International	43		39		132		119
Worldwide	81		76		245		230

Neuromodulation
U.S.	183		155		487		446
International	39		34		125		113
Worldwide	222		189		612		559

Interventional Cardiology
U.S.	327		283		942		859
International	373		332		1,126		1,062
Worldwide	700		615		2,067		1,922

Peripheral Interventions
U.S.	155		152		466		449
International	156		142		475		436
Worldwide	311		293		942		885

BTG Acquisition⁽¹⁾
Interventional Medicine	48		n/a		48		n/a
Specialty Pharmaceuticals	23		n/a		23		n/a
Worldwide	71		n/a		71		n/a

Net Sales	$	2,707	$	2,393	$	7,831	$	7,262

(1)

For the first nine months of 2019, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the BTG Acquisition into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the CODM. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs. Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.



	Three Months Ended September 30,				Nine Months Ended September 30,
Geographic Regions (Excluding BTG Acquisition)	2019		2018		2019		2018
U.S.	$	1,521	$	1,375	$	4,402	$	4,078
EMEA (Europe, Middle East and Africa)	530		498		1,662		1,619
APAC (Asia-Pacific)	484		425		1,402		1,282
Latin America and Canada	101		94		293		282
BTG Acquisition⁽¹⁾(Worldwide)	71		n/a		71		n/a
Net Sales	$	2,707	$	2,393	$	7,831	$	7,262

Emerging Markets⁽²⁾ (Excluding BTG Acquisition)	$	310	$	267	$	925	$	812


(1)	Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.

(2)

We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation. The revision had an immaterial impact on prior year Emerging Markets sales.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying unaudited condensed consolidated balance sheets. Our deferred revenue balance was $398 million as of September 30, 2019 and $373 million as of December 31, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $35 million in the third quarter of 2019 and $107 million in the first nine months of 2019 that was included in the above December 31, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit and record the amount for estimated sales returns as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.